Gene Overdosage and comorbidities during the early lifetime in Down Syndrome

Explore

News & Events

More news
30 June 2025

Celebrating more than 5 years of successful collaboration at the Final GA Meeting in Munich

After 66 months of dedicated collaboration, the GO-DS21 project has successfully concluded, marking a major milestone in advancing research on Down syndrome (DS) and co-occurring conditions. The final General Assembly (GA) in Munich from 6-8 May 2025 celebrated key scientific achievements, fostered meaningful dialogue with patient advocacy experts, and offered a special highlight in the form of a visit to the German Mouse Clinic, where cutting-edge research methods were shared. A heartfelt thank you to all partners and contributors - your commitment has laid a strong foundation for lasting impact in science and care for people with DS.

News & Events

More news
30 June 2025

Celebrating more than 5 years of successful collaboration at the Final GA Meeting in Munich

After 66 months of dedicated collaboration, the GO-DS21 project has successfully concluded, marking a major milestone in advancing research on Down syndrome (DS) and co-occurring conditions. The final General Assembly (GA) in Munich from 6-8 May 2025 celebrated key scientific achievements, fostered meaningful dialogue with patient advocacy experts, and offered a special highlight in the form of a visit to the German Mouse Clinic, where cutting-edge research methods were shared. A heartfelt thank you to all partners and contributors - your commitment has laid a strong foundation for lasting impact in science and care for people with DS.

Summary Statement

Clinicians, pathophysiologists, integrative bioinformaticians and artificial intelligence computer scientists working to unravel intrinsic and extrinsic mechanisms that impact on Down Syndrome (DS) comorbidity (focusing on obesity and intellectual disability. The examination of the pathways and mechanisms involved in comorbidities and multi-morbidities that induce the coexistence of two or more diseases in an individual is of major importance for the effective treatment of patients suffering from DS, obesity and mental disorders.

To achieve a system view to this disease we will integrate multiple datasets using new multi-layered approaches, which offer a unique opportunity for the integration and synthesis of molecular (multi-OMICS) preclinical (cellular and animal) and clinical datasets and metadata (environment, patient history) to understand the mechanisms of comorbidities.

In GO-DS21 we plan to use publicly available and self-developed bioinformatics tools, network science, statistical machine learning software and mathematical modeling approaches to unravel the shared etiological mechanisms in DS and the associated comorbidities, mainly obesity and intellectual disability.

Learn More

Our vision

Learn more

Why it matters

Learn more